The sharp guidance reduction for both Q3 and full-year 2026, combined with the recently announced $700M-$800M restructuring plan, signals a material growth deceleration and cost pressures. Traders should watch for further downside risk if Q3 guidance proves optimistic given the macro and tariff headwinds cited. The $1.5B MiRus investment and $2B buyback provide some offset but do not reverse the fundamental slowdown.
Price Chart
Executive Summary
Boston Scientific reported Q2 2026 adjusted EPS of $0.86, beating the $0.83 consensus by 3.6%, on revenue of $5.442B (7.5% reported growth, above the 5.5-7.5% guidance range). However, the company significantly lowered full-year 2026 guidance: organic revenue growth cut to 5-6% (from prior 6.5-8%) and adjusted EPS guidance reduced to $3.28-$3.32 (from $3.34-$3.41). The beat was overshadowed by the guidance cut and a 2-day-old restructuring plan (Item 2.05) with $700M-$800M in charges, signaling a material deceleration in the core business.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS of $0.86 beat consensus of $0.83 by 3.6%
- Q2 revenue of $5.442B grew 7.5% reported, at the high end of 5.5-7.5% guidance
- Full-year 2026 organic revenue growth guidance slashed to 5-6% from prior 6.5-8%
- Full-year 2026 adjusted EPS guidance lowered to $3.28-$3.32 from $3.34-$3.41
- Q3 2026 organic revenue growth guided to just 3-5%, a sharp deceleration
- Completed $2B accelerated share repurchase, repurchasing ~40M shares
- Invested $1.5B for ~34% equity stake in MiRus LLC with option to acquire TAVR business
- Restructuring plan (filed 2 days ago) carries $700M-$800M in pre-tax charges through 2029
Financial Impact
Full-year revenue growth guidance cut by ~150-200bps; EPS guidance cut by $0.06-$0.09 per share
Risk Factors
- Further revenue deceleration in H2 2026 if Q3 guidance proves too optimistic
- Restructuring execution risk and potential for additional charges
- Tariff and geopolitical headwinds impacting international operations
- Integration risk from MiRus investment and potential future acquisition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000885725-26-000051 |
| Document: bsx-20260729.htm | 0000885725-26-000051 |
| Document: 0000885725-26-000051-index-headers.html | 0000885725-26-000051 |
| Document: 0000885725-26-000051-index.html | 0000885725-26-000051 |
| Document: 0000885725-26-000051.txt | 0000885725-26-000051 |
| 8-K Data (Synthetic) | 0000885725-26-000051 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $48.30 $43.88 | ▼ −9.15% | ▼ −8.96% | $43.23 (−10.50%) |
Aug 26, 2026 5w ago | 8-K | $48.17 $43.72 | ▲ +9.24% | ▲ +10.44% | $43.23 (+10.26%) |
Aug 22, 2026 5w ago | Institutional Cluster | $49.01 $44.92 | ▼ −8.35% | ▼ −9.66% | $43.23 (−11.79%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $43.23 (−12.33%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $43.23 (−12.33%) |
Aug 5, 2026 8w ago | Insider Cluster | $47.74 $48.37 | ▲ +1.32% | ▲ +1.92% | $43.23 (−9.45%) |
Jul 29, 2026 9w ago | 8-K | $46.04 $48.17 | ▼ −4.63% | ▲ +0.39% | $43.23 (+6.10%) |
Jul 27, 2026 9w ago | 8-K | $46.06 $49.86 | ▲ +8.25% | ▲ +4.87% | $43.23 (−6.14%) |
Jul 27, 2026 9w ago | Court Ruling | $45.51 $49.01 | ▲ +7.69% | ▲ +4.39% | $43.23 (−5.01%) |
Jul 10, 2026 12w ago | Court Ruling | $44.77 $49.30 | ▲ +10.11% | ▲ +7.69% | $43.23 (−3.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access